RAPP·Nasdaq·US
Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for central nervous system disorders. Its pipeline includes programs for epilepsy, bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.
Recent Activity
Updated Oct 31, 2026
–Rapport Therapeutics announced proposed public offerings of common stock and convertible notes, along with a concurrent private placement.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.